Julie
is a real patient
with RA, performing
an everyday activity...
Indication
ACTEMRA, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, ACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.
Reference:
Actemra Product Information (HK). Current at August 2010
- © 2012 Roche Hong Kong Limited
This website contains information on products which is targeted to a wide range
of audiences and could contain product details or information otherwise not accessible or valid in
your country.
Please be aware that we do not take any responsibility for accessing such information which may
not comply with any legal process, regulation, registration or usage in the country of your origin.
Remark: This statement has been translated into Chinese. In case of inconsistency between the
English and Chinese versions, the English version shall prevail.